Pfizer Return on Investment 2012-2025 | PFE
Current and historical return on investment (ROI) values for Pfizer (PFE) over the last 10 years.
| Pfizer ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2025-12-31 | $14.24B | 12.80% | |
| 2025-09-30 | $13.72B | $150.51B | 9.28% |
| 2025-06-30 | $14.83B | $146.51B | 10.03% |
| 2025-03-31 | $12.05B | $148.28B | 8.16% |
| 2024-12-31 | $12.41B | $145.90B | 8.33% |
| 2024-09-30 | $5.78B | $150.56B | 3.85% |
| 2024-06-30 | $-2.35B | $145.48B | -1.55% |
| 2024-03-31 | $-1.16B | $153.87B | -0.75% |
| 2023-12-31 | $1.28B | $150.83B | 0.85% |
| 2023-09-30 | $10.79B | $158.25B | 7.44% |
| 2023-06-30 | $22.91B | $160.65B | 16.72% |
| 2023-03-31 | $32.93B | $132.94B | 25.88% |
| 2022-12-31 | $35.79B | $128.80B | 28.95% |
| 2022-09-30 | $33.55B | $125.52B | 28.00% |
| 2022-06-30 | $30.76B | $121.76B | 26.40% |
| 2022-03-31 | $24.15B | $118.34B | 21.47% |
| 2021-12-31 | $19.43B | $113.66B | 17.84% |
| 2021-09-30 | $17.15B | $112.22B | 16.22% |
| 2021-06-30 | $13.45B | $105.67B | 12.63% |
| 2021-03-31 | $9.91B | $104.21B | 9.11% |
| 2020-12-31 | $8.25B | $100.61B | 7.63% |
| 2020-09-30 | $2.62B | $115.28B | 2.43% |
| 2020-06-30 | $3.13B | $115.09B | 3.00% |
| 2020-03-31 | $5.32B | $101.62B | 5.34% |
| 2019-12-31 | $6.71B | $99.40B | 6.85% |
| 2019-09-30 | $5.62B | $101.44B | 5.78% |
| 2019-06-30 | $6.43B | $96.09B | 6.54% |
| 2019-03-31 | $6.14B | $94.89B | 6.20% |
| 2018-12-31 | $5.67B | $96.67B | 5.62% |
| 2018-09-30 | $14.00B | $105.32B | 13.59% |
| 2018-06-30 | $13.90B | $99.06B | 13.82% |
| 2018-03-31 | $13.66B | $102.37B | 13.80% |
| 2017-12-31 | $13.72B | $105.19B | 14.12% |
| 2017-09-30 | $13.17B | $95.61B | 14.06% |
| 2017-06-30 | $12.53B | $92.89B | 13.43% |
| 2017-03-31 | $12.26B | $95.08B | 13.12% |
| 2016-12-31 | $12.15B | $91.24B | 13.13% |
| 2016-09-30 | $12.22B | $94.04B | 13.13% |
| 2016-06-30 | $12.56B | $93.52B | 13.41% |
| 2016-03-31 | $12.68B | $91.17B | 13.52% |
| 2015-12-31 | $11.82B | $93.74B | 12.42% |
| 2015-09-30 | $12.14B | $96.20B | 12.44% |
| 2015-06-30 | $12.46B | $93.91B | 12.34% |
| 2015-03-31 | $12.82B | $96.96B | 12.23% |
| 2014-12-31 | $13.25B | $103.16B | 12.38% |
| 2014-09-30 | $14.15B | $109.97B | 13.10% |
| 2014-06-30 | $14.45B | $109.22B | 13.37% |
| 2014-03-31 | $14.78B | $105.72B | 13.64% |
| 2013-12-31 | $15.18B | $107.08B | 13.74% |
| 2013-09-30 | $14.70B | $110.17B | 13.13% |
| 2013-06-30 | $14.46B | $110.51B | 12.83% |
| 2013-03-31 | $15.04B | $114.31B | 13.34% |
| 2012-12-31 | $15.26B | $112.71B | 13.45% |
| 2012-09-30 | $14.62B | $113.20B | 12.74% |
| 2012-06-30 | $14.96B | $110.83B | 12.69% |
| 2012-03-31 | $14.12B | $117.22B | 11.63% |
| 2011-12-31 | $13.97B | $117.55B | 11.31% |
| 2011-09-30 | $13.94B | $125.93B | 11.08% |
| 2011-06-30 | $13.62B | $124.69B | 10.80% |
| 2011-03-31 | $13.80B | $125.84B | 10.94% |
| 2010-12-31 | $13.41B | $126.68B | 10.59% |
| 2010-09-30 | $11.49B | $127.08B | 8.94% |
| 2010-06-30 | $11.85B | $124.64B | 9.77% |
| 2010-03-31 | $10.77B | $128.36B | 9.46% |
| 2009-12-31 | $10.96B | $133.64B | 10.72% |
| 2009-09-30 | $13.43B | $98.65B | 15.76% |
| 2009-06-30 | $12.75B | $95.10B | 16.09% |
| 2009-03-31 | $12.25B | $81.51B | 16.58% |
| 2008-12-31 | $11.73B | $65.70B | 16.20% |
| 2008-09-30 | $11.65B | $74.49B | 15.73% |
| 2008-06-30 | $8.58B | $73.82B | 11.66% |
| 2008-03-31 | $7.09B | $75.56B | 9.64% |
| 2007-12-31 | $7.52B | $72.32B | 10.16% |
| 2007-09-30 | $6.93B | $72.65B | 9.21% |
| 2007-06-30 | $10.17B | $73.87B | 13.41% |
| 2007-03-31 | $11.76B | $77.26B | 15.51% |
| 2006-12-31 | $12.12B | $76.90B | 16.05% |
| 2006-09-30 | $13.03B | $75.27B | 17.52% |
| 2006-06-30 | $11.27B | $73.94B | 15.32% |
| 2006-03-31 | $11.26B | $76.12B | 15.47% |
| 2005-12-31 | $11.20B | $72.11B | 15.49% |
| 2005-09-30 | $12.08B | $72.22B | 16.52% |
| 2005-06-30 | $14.46B | $70.85B | 19.49% |
| 2005-03-31 | $15.07B | $73.96B | 20.14% |
| 2004-12-31 | $14.21B | $75.56B | 18.84% |
| 2004-09-30 | $12.68B | $76.34B | 17.07% |
| 2004-06-30 | $10.82B | $73.47B | 14.63% |
| 2004-03-31 | $3.94B | $76.19B | 5.27% |
| 2003-12-31 | $4.26B | $71.13B | 6.76% |
| 2003-09-30 | $5.56B | $74.97B | 10.92% |
| 2003-06-30 | $6.14B | $76.99B | 16.30% |
| 2003-03-31 | $12.02B | $28.56B | 50.27% |
| 2002-12-31 | $11.59B | $23.09B | 51.91% |
| 2002-09-30 | $10.45B | $22.07B | 47.97% |
| 2002-06-30 | $10.24B | $21.90B | 47.62% |
| 2002-03-31 | $10.32B | $22.25B | 48.95% |
| 2001-12-31 | $9.89B | $20.90B | 48.41% |
| 2001-09-30 | $7.92B | $20.98B | 40.59% |
| 2001-06-30 | $6.92B | $20.18B | 37.20% |
| 2001-03-31 | $5.99B | $19.64B | 33.97% |
| 2000-12-31 | $3.74B | $17.20B | 24.27% |
| 2000-09-30 | $4.82B | $17.43B | 35.86% |
| 2000-06-30 | $3.42B | $16.24B | 29.96% |
| 2000-03-31 | $3.02B | $10.71B | 31.32% |
| 1999-12-31 | $3.89B | $9.41B | 41.49% |
| 1999-09-30 | $3.90B | $9.31B | 41.67% |
| 1999-06-30 | $4.52B | $9.18B | 48.57% |
| 1999-03-31 | $3.91B | $9.57B | 42.11% |
| 1998-12-31 | $3.41B | $9.34B | 37.36% |
| 1998-09-30 | $2.41B | $9.17B | 26.90% |
| 1998-06-30 | $1.87B | $9.03B | 21.48% |
| 1998-03-31 | $1.69B | $8.92B | 20.08% |
| 1997-12-31 | $1.58B | $8.66B | 19.41% |
| 1997-09-30 | $1.79B | $8.13B | 22.70% |
| 1997-06-30 | $2.18B | $7.91B | 28.58% |
| 1997-03-31 | $2.54B | $7.88B | 34.81% |
| 1996-12-31 | $2.80B | $7.64B | 40.35% |
| 1996-09-30 | $2.83B | $7.12B | 42.67% |
| 1996-06-30 | $2.68B | $6.57B | 42.90% |
| 1996-03-31 | $2.50B | $6.47B | 41.91% |
| 1995-12-31 | $2.30B | $6.34B | 40.46% |
| 1995-09-30 | $2.25B | $5.64B | 42.30% |
| 1995-06-30 | $2.07B | $5.44B | 40.56% |
| 1995-03-31 | $2.01B | $5.31B | 41.71% |
| 1994-12-31 | $1.97B | $4.93B | 42.90% |
| 1994-09-30 | $1.88B | $4.74B | 41.91% |
| 1994-06-30 | $1.82B | $4.32B | 41.39% |
| 1994-03-31 | $1.74B | $4.41B | 38.68% |
| 1993-12-31 | $1.67B | $4.44B | 35.73% |
| 1993-09-30 | $1.62B | $4.40B | 33.16% |
| 1993-06-30 | $1.57B | $4.78B | 29.70% |
| 1993-03-31 | $1.52B | $5.03B | 27.68% |
| 1992-12-31 | $1.44B | $5.29B | 25.53% |
| 1992-09-30 | $1.35B | $6.06B | 23.69% |
| 1992-06-30 | $1.32B | $5.62B | 24.05% |
| 1992-03-31 | $1.29B | $5.64B | 24.26% |
| 1991-12-31 | $1.25B | $5.42B | 23.91% |
| 1991-09-30 | $1.20B | $5.22B | 23.10% |
| 1991-06-30 | $1.16B | $4.99B | 22.28% |
| 1991-03-31 | $1.12B | $5.36B | 21.67% |
| 1990-12-31 | $1.05B | $5.29B | 20.79% |
| 1990-09-30 | $1.02B | $5.20B | 20.59% |
| 1990-06-30 | $0.98B | $4.86B | 20.38% |
| 1990-03-31 | $0.95B | $4.93B | 20.09% |
| 1989-12-31 | $0.97B | $4.73B | 20.72% |
| 1989-09-30 | $0.97B | $4.73B | 20.92% |
| 1989-06-30 | $0.97B | $4.53B | 21.30% |
| 1989-03-31 | $1.05B | $4.70B | 23.27% |
| 1988-12-31 | $1.01B | $4.53B | 22.79% |
| 1988-09-30 | $1.01B | $4.48B | 23.20% |
| 1988-06-30 | $0.99B | $4.37B | 23.46% |
| 1988-03-31 | $0.99B | $4.37B | 24.06% |
| 1987-12-31 | $0.94B | $4.13B | 23.60% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $156.812B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |